Impact of variable titer COVID-19 convalescent plasma and recipient SARS-CoV2-specific humoral immunity on survival in hospitalized patients
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0309449 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Carlo J Iasella und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania, United States of America. Hauptthemen laut MEDLINE: COVID-19, Immunization, Passive, COVID-19 Serotherapy, SARS-CoV-2. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, Pittsburgh Foundation, David Scaife Foundation.
Abstract (Originalsprache)
COVID-19 convalescent plasma (CCP) was one of the first therapies to receive emergency use authorization for management of COVID-19. We assessed the effectiveness of CCP in a propensity-matched analysis, and whether the presence of antibodies in the recipient at the time of treatment or the titer of antibodies in the administered CCP influenced clinical effectiveness. In an inpatient population within a single large health system, a total of 290 CCP patients were matched to 290 controls. While CCP increased titers of anti-SARS-CoV-2 RBD IgG titers post-CCP (p =
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania, United States of America.
- Department of Medicine, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.
- Department of Medicine, Aging Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.
- Department of Medicine, Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.
- Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America.
- Department of Pathology, Division of Transfusion Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.
ORCID-Profile: Carlo J Iasella, Melissa Saul, Ioannis Konstantinidis
Förderung
- NHLBI NIH HHS
- Pittsburgh Foundation
- David Scaife Foundation
Zitieren
APA
Iasella, C. J., Hannan, S. J., Lyons, E. J., Lieber, S. C., Das, A., Dimitrov, D., Li, W., Saul, M., Popescu, I., Koshy, R., Burke, R., Lape, B., Brown, M. J., Chen, X., Sembrat, J. C., Devonshire, K., Kitsios, G. D., Konstantinidis, I., Snyder, M. E., …, & McDyer, J. F. (2024). Impact of variable titer COVID-19 convalescent plasma and recipient SARS-CoV2-specific humoral immunity on survival in hospitalized patients. PLOS ONE. https://doi.org/10.1371/journal.pone.0309449
Vancouver
Iasella CJ, Hannan SJ, Lyons EJ, Lieber SC, Das A, Dimitrov D, et al. Impact of variable titer COVID-19 convalescent plasma and recipient SARS-CoV2-specific humoral immunity on survival in hospitalized patients. PLOS ONE. 2024. doi:10.1371/journal.pone.0309449
BibTeX
@article{Iasella2024,
author = {Iasella, Carlo J and Hannan, Stefanie J and Lyons, Emily J and Lieber, Sophia C and Das, Antu and Dimitrov, Dimiter and Li, Wei and Saul, Melissa and Popescu, Iulia and Koshy, Ritchie and Burke, Robin and Lape, Braidon and Brown, Mark J and Chen, Xiaoping and Sembrat, John C and Devonshire, Kaitlyn and Kitsios, Georgios D and Konstantinidis, Ioannis and Snyder, Mark E and Chen, Bill B and Merlo, Christian A and Hager, David N and Kiss, Joseph E and Yazer, Mark H and Wells, Alan H and Morris, Alison and McVerry, Bryan J and McMahon, Deborah K and Triulzi, Darrell J and McDyer, John F},
title = {Impact of variable titer COVID-19 convalescent plasma and recipient SARS-CoV2-specific humoral immunity on survival in hospitalized patients},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0309449}
}
EUVIMED